FTC approves modifications to Boston Scientific divestiture agreement
- Select a language for the TTS:
- UK English Female
- UK English Male
- US English Female
- US English Male
- Australian Female
- Australian Male
- Language selected: (auto detect) - EN
Play all audios:
(Reuters) – The U.S. Federal Trade Commission said it has approved certain modifications to medical device company Boston Scientific Corp’s divestiture agreements.
“The FTC approved these agreements and incorporated them into its order as part of a consent agreement it required in 2019, when Boston Scientific acquired medical equipment and
pharmaceutical supplier BTG plc,” the FTC said in a statement https://bit.ly/3Bv08z0 on Friday.
As a condition of Boston Scientific’s acquisition of BTG, the FTC required it to divest to Varian Medical Systems its Drug Eluding Beads (DEBs) and bland beads business, the FTC said.
(Reporting by Kanishka Singh in Bengaluru; Editing by Chris Reese)
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.